Game-changer for prostate cancer? AstraZeneca’s Truqap shows remarkable results in pivotal trial
AstraZeneca has announced results from its CAPItello-281 Phase III trial, revealing that Truqap (capivasertib), when combined with abiraterone and androgen deprivation therapy (ADT), significantly improves ... Read More
AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) for approval within ... Read More
FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More